Form 10-Q ACADIA PHARMACEUTICALS For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- SpaceX slides, tech stocks dip — what’s moving markets
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at Needham & Company
August 5, 2021 6:30 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "ACAD reported $115.2M in 2Q21 Nuplazid sales, below our $130.0M and consensus $126.3M ests. Sales +vely impacted by volume... More
